- Home
- REGN vs E Comparison
REGN vs E Comparison
Compare REGN & E Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REGN | E |
|---|---|---|
| Founded | 1988 | 1953 |
| Country | United States | Italy |
| Employees | N/A | 32349 |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.5B | 77.3B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | REGN | E |
|---|---|---|
| Price | $699.02 | $55.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 3 |
| Target Price | ★ $830.16 | $28.00 |
| AVG Volume (30 Days) | ★ 695.9K | 410.6K |
| Earning Date | 04-29-2026 | 04-24-2026 |
| Dividend Yield | 0.55% | ★ 2.97% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 6.75 | N/A |
| Revenue | ★ $5,872,227,000.00 | N/A |
| Revenue This Year | $12.45 | $11.36 |
| Revenue Next Year | $10.13 | N/A |
| P/E Ratio | $105.86 | ★ $21.46 |
| Revenue Growth | ★ 20.82 | N/A |
| 52 Week Low | $476.49 | $28.78 |
| 52 Week High | $821.11 | $58.00 |
Technical Indicators
Market Signals| Indicator | REGN | E |
|---|---|---|
| Relative Strength Index (RSI) | 39.31 | 53.63 |
| Support Level | $679.36 | $52.24 |
| Resistance Level | $783.87 | $57.50 |
| Average True Range (ATR) | 19.66 | 0.77 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 34.75 | 64.78 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About E ENI S.p.A.
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2024, the company produced 0.8 million barrels of liquids and 4.8 billion cubic feet of natural gas per day. At end-2024, Eni held reserves of 6.5 billion barrels of oil equivalent, 46% of which are liquids. The Italian government owns a 30.5% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity called Plenitude, which it will likely list publicly at some point.